Zolpidem Arouses Patients in Vegetative State After Brain Injury: Quantitative Evaluation and Indications

GABAA receptor deficits predict recovery in patients with disorders of consciousness: A preliminary multimodal [11C]Flumazenil PET and fMRI study

“…With the introduction of Zolpidem, GABA receptor function may be returned to normal, ceasing the dormant state. Based on our findings, one would predict that the subset of patients who are reactive to Zolpidem [Whyte et al, ] might show particularly high degrees of GABA A receptor binding when compared with those that do not [Ciurleo et al, ; Du et al, ; Singh et al, ].…”

Improved Arousal and Motor Function Using Zolpidem in a Patient With Space‐Occupying Intracranial Lesions: A Case Report

“…To our knowledge, this is one of the first reports of its off‐label use in this population. In 2014, Du et al [8] performed a study in which they obtained single‐photon positron emission tomography and cerebral state monitoring before and 1 hour after administering zolpidem to 165 subjects in a VS. Of these subjects, 40 had brain injury due to a space‐occupying mass, typically either a tumor or hematoma. As a group they showed significant improvement across all measures.…”

Metal-free, efficient hydrazination of imidazo[1,2-a]pyridine with diethyl azodicarboxylate in neutral media

“…1 For example, they exhibit good anti-cancer, 2 anti-inflammatory, 3 anti-bacterial, 4 anti-protozonal, 5 anti-viral, 6 anti-ulcer, 7 anti-fungal, 8 and anxiolytic properties. In addition, imidazo[1,2-a]pyridines have been found to be the core structure of many natural products and marketed drugs, including alpidem, 9 necopidem, 10 saripidem, 11 zolpidem (Ambien ®), 12 olprinone, 13 DS-1, 14 minodronic acid, 15 divalpon, 16 and Zolimidine. 17 In fact, imidazo[1,2-a]pyridines are key scaffolds in the non-benzodiazepine drug class, which bind the GABA-A receptor and are first line treatments for insomnia and benzodiazepine-resistant anxiety disorders.…”